SHA: 688235

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Huahui Health, a Beijing-based biotechnology company focused on viral hepatitis, hepatology, and oncology, announced a...

Company Drug

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

Fineline Cube Apr 10, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China’s National...

Company

BeOne Medicines Reports $5.3B Full‑Year Revenue – Brukinsa Drives 40% Growth, 2026 Guidance Raised

Fineline Cube Feb 27, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q4 and full‑year 2025 financial results, with global...

Company Drug

BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL

Fineline Cube Jan 8, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its self‑developed Class 1 innovative drug...

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Fineline Cube Dec 21, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. Food and Drug...

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Fineline Cube Dec 20, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai...

Company Drug

BeOne’s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma

Fineline Cube Nov 27, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. FDA has accepted its...

Company Drug

BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial

Fineline Cube Nov 18, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced its HER2‑targeted bispecific antibody zanidatamab (Ziihera)...

Company

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum

Fineline Cube Nov 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released its third‑quarter 2025 financial results, reporting...

Company Drug

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma

Fineline Cube Oct 14, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food...

Company Legal / IP

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors

Fineline Cube Oct 11, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated...

Company Deals

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights

Fineline Cube Aug 26, 2025

On August 26, 2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had...

Company

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales

Fineline Cube Aug 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business...

Company Drug

BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia

Fineline Cube Aug 1, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced on July 31, 2025,...

Company Drug

BeOne Medicines’ Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment

Fineline Cube Jul 29, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its PD-1 antibody...

Company Drug

BeOne Medicines’ Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma

Fineline Cube Jul 11, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Company Deals

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement

Fineline Cube Jul 10, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...

Company Drug

EMA Panel Recommends Brukinsa Tablet Formulation for Approval

Fineline Cube Jun 26, 2025

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China

Fineline Cube Jun 25, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced the official commercial availability...

Company

Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move

Fineline Cube Jun 18, 2025

Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...

SHA: 688235

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

BeOne Medicines Reports $5.3B Full‑Year Revenue – Brukinsa Drives 40% Growth, 2026 Guidance Raised

BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

BeOne Medicines Names Dual Presidents in Leadership Overhaul

BeOne’s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma

BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales

BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia

BeOne Medicines’ Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment

BeOne Medicines’ Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement

EMA Panel Recommends Brukinsa Tablet Formulation for Approval

BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China

Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move

You Missed

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets